Akinwale Olatosi
Infectious Disease · Camden, SCNPI 1740201680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,530 of the $16,952 with a category attached, or 73.9%. 11 manufacturers reported payments, led by Viiv Healthcare Company at 52.6% of the total. Reporting peaked in 2021 at $10,960 and has fallen 98.6% since, to $150 in 2025. Among infectious disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $169.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$9K
- Gilead$8K
- Janssen Products, LP$121
- Theratechnologies Inc.$103
- Napo Pharmaceuticals Inc$61
- Merck$50
- plus $147 from 5 others
What the payments were for
- Consulting fees$2,76016%
- Speaking & faculty fees$12,53074%
- Food & beverage$1,5959%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 47 | $8,910 |
| Gilead | 28 | $7,560 |
| Janssen Products, LP | 2 | $121 |
| Theratechnologies Inc. | 5 | $103 |
| Napo Pharmaceuticals Inc | 5 | $61 |
| Merck | 3 | $50 |
| Johnson & Johnson | 4 | $48 |
| AbbVie(2 entities) | 3 | $43 |
| Dexcom, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,952 in reported general payments places this provider in the 90th percentile of 102 infectious disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 1,415 | $5,416,505 |
| TivicayDolutegravir Sodium | 403 | $975,828 |
| DescovyEmtricitabine/Tenofov Alafenam | 340 | $718,267 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 94 | $330,136 |
| IsentressRaltegravir Potassium | 140 | $267,901 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 27 | $123,431 |
| PrezcobixDarunavir/Cobicistat | 20 | $44,957 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $43,086 |
| JulucaDolutegravir/Rilpivirine | 11 | $35,853 |
| Darunavir | 69 | $26,559 |
| Isentress HdRaltegravir Potassium | 14 | $25,191 |
| Etravirine | 23 | $24,899 |
| EdurantRilpivirine Hcl | 14 | $20,524 |
| AbacavirAbacavir Sulfate | 58 | $5,397 |
| Ritonavir | 53 | $4,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Tybost | $7,560 | $6,138,1241,767 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Juluca | $8,910 | $1,054,767427 claims |
| MerckIsentress, Isentress Hd | $50 | $293,092154 claims |
| Janssen Products, LPSymtuza | $121 | $123,43127 claims |
| Johnson & JohnsonPrezcobix | $48 | $44,95720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 102 infectious disease providers in South Carolina.
Other infectious disease in Camden
- Timothy HenkelHilton Head Island$1.8M
- Toby FugateCharleston$136K
- John McKinnonCharleston$85K
- John SchrankGreenville$74K
- Rishika MotianiFlorence$43K
- John GnannCharleston$39K
- John SamiesOrangeburg$18K
- Robert BallNorth Charleston$14K
- Eunice GuzmanMyrtle Beach$10K
- Scott CurryCharleston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.